CY1125699T1 - Συνθεσεις mycoplasma bovis - Google Patents

Συνθεσεις mycoplasma bovis

Info

Publication number
CY1125699T1
CY1125699T1 CY20221100762T CY221100762T CY1125699T1 CY 1125699 T1 CY1125699 T1 CY 1125699T1 CY 20221100762 T CY20221100762 T CY 20221100762T CY 221100762 T CY221100762 T CY 221100762T CY 1125699 T1 CY1125699 T1 CY 1125699T1
Authority
CY
Cyprus
Prior art keywords
compositions
bovis
mycoplasma bovis
disclosed
mycoplasma
Prior art date
Application number
CY20221100762T
Other languages
English (en)
Inventor
Glenn Francis Browning
Philip Francis MARKHAM
Marc Serge MARENDA
Fred H. Weber
Suman MAHAN
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of CY1125699T1 publication Critical patent/CY1125699T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/35—Mycoplasma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Αποκαλυπτόμενες στο παρόν είναι ανοσογονικές συνθέσεις Mycoplasma bovis χρήσιμες στην έγερση ανοσοαπόκρισης σε ζώα έναντι Μ. bovis. Επίσης αποκαλυπτόμενες στο παρόν είναι μέθοδοι για δημιουργία προστατευτικής απόκρισης έναντι μολύνσεων σε θηλαστικά που προκαλούνται από Μ. bovis.
CY20221100762T 2015-08-14 2022-12-02 Συνθεσεις mycoplasma bovis CY1125699T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562205125P 2015-08-14 2015-08-14
PCT/US2016/046572 WO2017030901A1 (en) 2015-08-14 2016-08-11 Mycoplasma bovis compositions

Publications (1)

Publication Number Publication Date
CY1125699T1 true CY1125699T1 (el) 2024-02-16

Family

ID=56800367

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20221100762T CY1125699T1 (el) 2015-08-14 2022-12-02 Συνθεσεις mycoplasma bovis
CY2023020C CY2023020I2 (el) 2015-08-14 2023-10-03 Συνθεσεις mycoplasma bovis

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2023020C CY2023020I2 (el) 2015-08-14 2023-10-03 Συνθεσεις mycoplasma bovis

Country Status (23)

Country Link
US (2) US11389518B2 (el)
EP (2) EP3334454B1 (el)
JP (1) JP6675484B2 (el)
CN (3) CN115141773A (el)
AU (2) AU2016307935B2 (el)
BR (1) BR112018002919B1 (el)
CA (1) CA2995101A1 (el)
CY (2) CY1125699T1 (el)
DK (1) DK3334454T3 (el)
ES (1) ES2933623T3 (el)
FI (1) FI3334454T3 (el)
FR (1) FR23C1037I1 (el)
HK (1) HK1251478A1 (el)
HR (1) HRP20221440T1 (el)
HU (2) HUE060545T2 (el)
LT (1) LT3334454T (el)
MX (1) MX2018001841A (el)
NL (1) NL301244I2 (el)
PL (1) PL3334454T3 (el)
PT (1) PT3334454T (el)
SI (1) SI3334454T1 (el)
WO (1) WO2017030901A1 (el)
ZA (1) ZA201800956B (el)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109022314B (zh) * 2018-08-06 2021-08-13 北京华夏兴洋生物科技有限公司 一株牛支原体及其在疫苗研制中的应用
CN111471695A (zh) * 2020-05-11 2020-07-31 吉林农业大学 牛支原体免疫磁珠的制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
AU672359B2 (en) 1991-03-07 1996-10-03 Virogenetics Corporation Genetically engineered vaccine strain
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
WO1993013302A1 (de) 1991-12-23 1993-07-08 Michael Zoche Motor mit einer vorrichtung zur entölung
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
CA2247336C (en) 1996-02-28 2008-06-17 Bayer Aktiengesellschaft Parapoxviruses containing foreign dna, their production and their use in vaccines
KR100780158B1 (ko) 1996-10-23 2007-11-27 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 면역 치료법 및 개량 백신
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
ATE512231T1 (de) 1998-02-27 2011-06-15 Univ Pennsylvania Impfstoffe, immuntherapeutika und verfahren zur anwendung derselben
WO1999045966A1 (en) 1998-03-13 1999-09-16 American Home Products Corporation Polynucleotide composition, method of preparation, and use thereof
IL142231A0 (en) 1998-09-30 2002-03-10 American Cyanamid Co Mutant cholera holotoxin as an adjuvant
JP2003513935A (ja) 1999-11-08 2003-04-15 バイオミューン マイコプラズマ・ボビスに対するワクチンおよび使用方法
US6548069B2 (en) 2001-02-03 2003-04-15 Hmv Associates, Inc. Multivalent Mycoplasma bacterin
GB0110851D0 (en) 2001-05-03 2001-06-27 Mini Agriculture & Fisheries Vaccine
WO2002098369A2 (en) 2001-06-07 2002-12-12 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
ATE451386T1 (de) 2001-06-07 2009-12-15 Wyeth Corp Mutantenformen von cholera holotoxin als adjuvans
US20030147914A1 (en) 2001-07-02 2003-08-07 Pfizer Inc. Mycoplasma bovis vaccine and methods of reducing pneumonia in animals
CA2515890C (en) 2003-02-20 2013-09-17 Therion Biologics Corporation Novel insertion sites in pox vectors
US20090068231A1 (en) * 2007-09-11 2009-03-12 Wyeth Live attenuated mycoplasma strains
UY31437A1 (es) * 2007-10-29 2009-05-29 Vacuna de mycoplasma bovis y métodos de uso de la misma
AU2009265092B2 (en) 2008-07-03 2015-09-03 Biotechnology Research And Development Corporation Cattle vaccines
US8815255B2 (en) * 2008-10-31 2014-08-26 Boehringer Ingelheim Vetmedica, Inc. Use of Mycoplasma bovis antigen
CN102317439B (zh) * 2009-02-20 2015-11-25 澳大利亚家禽Crc有限公司 减毒活疫苗
UY32570A (es) * 2009-04-24 2010-11-30 Boehringer Ingelheim Vetmed Vacuna viva modificada de mycoplasma bovis mejorada

Also Published As

Publication number Publication date
BR112018002919A2 (pt) 2018-09-18
DK3334454T3 (da) 2022-11-14
JP2018523708A (ja) 2018-08-23
WO2017030901A1 (en) 2017-02-23
AU2016307935A1 (en) 2018-02-22
US20220296694A1 (en) 2022-09-22
PL3334454T3 (pl) 2023-01-30
US11389518B2 (en) 2022-07-19
HUS2300032I1 (hu) 2024-07-28
HUE060545T2 (hu) 2023-03-28
BR112018002919B1 (pt) 2024-02-27
CN108135989A (zh) 2018-06-08
HK1251478A1 (zh) 2019-02-01
EP4137152A1 (en) 2023-02-22
HRP20221440T1 (hr) 2023-02-03
CY2023020I1 (el) 2024-02-16
CA2995101A1 (en) 2017-02-23
PT3334454T (pt) 2022-12-20
MX2018001841A (es) 2018-08-01
NL301244I2 (nl) 2023-11-01
EP3334454A1 (en) 2018-06-20
EP3334454B1 (en) 2022-10-19
AU2022231761A1 (en) 2022-10-06
CN108135989B (zh) 2022-08-09
ZA201800956B (en) 2018-12-19
FI3334454T3 (fi) 2023-01-13
ES2933623T3 (es) 2023-02-10
FR23C1037I1 (fr) 2023-12-08
JP6675484B2 (ja) 2020-04-01
CN115141772A (zh) 2022-10-04
SI3334454T1 (sl) 2023-02-28
CN115141773A (zh) 2022-10-04
CY2023020I2 (el) 2024-02-16
AU2016307935B2 (en) 2022-08-18
US20190255166A1 (en) 2019-08-22
NL301244I1 (nl) 2023-10-04
LT3334454T (lt) 2022-12-27

Similar Documents

Publication Publication Date Title
CY1124131T1 (el) Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου
MA46766A (fr) Vaccin antigrippal
CY1125699T1 (el) Συνθεσεις mycoplasma bovis
CY1122329T1 (el) Anti-siglec-8 αντισωματα και μeθοδοι χρhσεως αυτων
DK3612557T3 (da) Antigenspecifikke immuneffektorceller
MA43762A (fr) Vaccin contre le rsv
CL2016001708A1 (es) Determinantes de respuesta del cáncer a la inmunoterapia
CL2016002849A1 (es) Oligómeros y conjugados de oligómeros
BR112017009374A2 (pt) ?composições de ramnolipídeo de baixa viscosidade concentradas?
BR112017003414A2 (pt) composições compreendendo caseína e métodos para produzir as mesmas
DK3218504T3 (da) Trisegmenterede arenavira som vaccinevektorer
MA46661A (fr) Formulations de vaccin glycoconjugué dirigé contre expec
CY1123574T1 (el) Αντιπολλαπλασιαστικες ενωσεις και φαρμακευτικες συνθεσεις και χρησεις αυτων
DK3414505T3 (da) Mekanisk damprekompressionsindretning
DK3538542T3 (da) Cykliske peptidmultimerer målrettet alfa-4beta-7-integrin
BR112018005412A2 (pt) animais geneticamente modificados que possuem tolerância térmica aumentada.
UA116697C2 (uk) Композиція для запобігання зараженню видами роду mycoplasma
DK3607646T3 (da) Molekylær maskine
DK3571208T3 (da) Immunproteasominhibitorer
DK3458080T3 (da) Polypeptidmodulerende siglec-afhængige immunreaktioner
BR112016026034A2 (pt) intercepção de conexões interativa baseada em comunicações de rede em que o estado oferece mensagens segmentadas, com base no estado
MA45165A (fr) Polypeptides antigéniques de la grippe modifiés et compositions immunogéniques associées
DK3414973T3 (da) Varmegenerator
EA201690378A1 (ru) Вакцинные композиции против наркотической зависимости
DK3604802T3 (da) Energigenereringssystem